Iraqi Journal of Hematology

Scope & Guideline

Empowering Research, Enhancing Patient Care

Introduction

Welcome to your portal for understanding Iraqi Journal of Hematology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2072-8069
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationIRAQI J HEMATOL / Iraqi J. Hematol.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Iraqi Journal of Hematology serves as a pivotal platform for disseminating research and advancements in hematology, with a strong emphasis on clinical studies and diagnostic innovations. The journal focuses on a variety of hematological conditions, treatments, and the implications of emerging research in the field.
  1. Clinical Research in Hematology:
    The journal publishes clinical studies that assess treatment outcomes, diagnostic techniques, and patient management strategies for various hematological disorders, such as leukemia, thalassemia, and lymphoma.
  2. Diagnostic Innovations:
    There is a consistent focus on the evaluation and comparison of diagnostic methods, including novel techniques for blood tests and cross-matching, which contribute to improved patient outcomes.
  3. Epidemiological Studies:
    The journal frequently includes epidemiological research that examines the prevalence and risk factors associated with hematological diseases within specific populations, particularly in Iraq.
  4. Therapeutic Interventions:
    Research on the efficacy and safety of treatment regimens, including chemotherapy, stem cell transplantation, and novel therapies, is a core area of the journal's focus.
  5. Patient-Centered Outcomes:
    Studies that explore quality of life, patient experiences, and the psychosocial aspects of living with hematological conditions are also highlighted, reflecting a comprehensive approach to patient care.
Recent publications in the Iraqi Journal of Hematology indicate a dynamic evolution of research themes, with several emerging scopes gaining traction. These trends are reflective of both global advancements and localized health concerns.
  1. Impact of COVID-19 on Hematological Patients:
    There is an increasing focus on how COVID-19 affects patients with existing hematological conditions, including complications and treatment outcomes, which is crucial given the pandemic's widespread impact.
  2. Personalized Medicine and Genetic Studies:
    Emerging research on the genetic factors influencing treatment responses in hematological diseases underscores a growing interest in personalized medicine, aiming to tailor treatments based on individual genetic profiles.
  3. Nutritional and Environmental Factors:
    Recent studies evaluating the role of nutritional deficiencies, such as Vitamin D levels in thalassemia patients, highlight a trend towards understanding how environmental and lifestyle factors affect hematological health.
  4. Innovative Therapeutics and Treatment Regimens:
    There is a marked increase in studies assessing novel therapies and regimens for hematological diseases, reflecting ongoing advancements in treatment methodologies and patient management.
  5. Quality of Life and Patient Experience Research:
    An emerging theme is the assessment of quality of life and psychosocial factors among patients with hematological disorders, emphasizing the importance of holistic patient care.

Declining or Waning

While the Iraqi Journal of Hematology continues to thrive in several areas, certain themes are becoming less prominent over time, reflecting shifts in research focus and clinical priorities.
  1. Basic Science Research:
    There is a noticeable decrease in the number of publications focusing on the fundamental biological and molecular mechanisms underlying hematological diseases, suggesting a shift towards more clinically relevant studies.
  2. Rare Hematological Disorders:
    Research on rare hematological conditions appears to be declining, possibly due to a reduced number of cases and the challenges associated with studying these less common disorders.
  3. Historical and Longitudinal Studies:
    The journal has seen fewer studies that focus on historical perspectives or long-term outcomes of hematological treatments, indicating a preference for current and immediate clinical applications.

Similar Journals

EUROPEAN JOURNAL OF HAEMATOLOGY

Advancing Hematology Research for a Healthier Tomorrow
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

LEUKEMIA & LYMPHOMA

Transforming the landscape of cancer treatment and care.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

BLOOD REVIEWS

Fostering innovation in the science of blood.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Mediterranean Journal of Hematology and Infectious Diseases

Connecting scholars to elevate hematology and infectious disease studies.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

BONE MARROW TRANSPLANTATION

Connecting Researchers to Transform Transplantation Practices.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Journal of Hematology

Innovating Insights into Blood Disorders
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Advancing pediatric health through innovative research.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Therapeutic Advances in Hematology

Transforming research into impactful therapies.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Lancet Haematology

Transforming the future of hematology, one study at a time.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

International Journal of Laboratory Hematology

Empowering researchers with cutting-edge findings in hematology.
Publisher: WILEYISSN: 1751-5521Frequency: 6 issues/year

The International Journal of Laboratory Hematology, published by WILEY, serves as a vital resource in the field of hematology, delivering high-quality research findings and innovations within laboratory practices since its inception in 2007. This journal, accessible under Open Access options, showcases cutting-edge studies that span critical aspects of biochemistry and clinical laboratory methodologies. With a notable impact factor reflected in its Q2 and Q3 rankings across various categories—such as Biochemistry (medical) and Hematology—this journal stands out within the Scopus rankings, positioning itself within the 60th and 59th percentiles of its respective fields. Situated in the United Kingdom, the journal's objectives lie in disseminating pivotal research that enhances our understanding of hematological disorders and laboratory techniques, making it an essential tool for researchers, professionals, and students alike who are committed to advancing the science of laboratory hematology and its applications.